Kindstar Globalgene Technology, Inc. (HKEX: 09960) executed an on-market share repurchase of 31,500 ordinary shares on 21 July 2026. The buyback, carried out under the mandate approved on 5 June 2026, was completed at prices ranging from HK$0.96 to HK$1.00 per share, with a volume-weighted average cost of HK$0.9837. The total consideration amounted to HK$0.03 million.

Post-transaction, Kindstar’s issued share capital (excluding treasury shares) decreased by 0.00305% to 1.03 billion shares, while treasury shares increased to 8.02 million. The company’s overall share count, including treasury shares, remains unchanged at 1.04 billion.

Since the current mandate took effect, the company has repurchased an aggregate 953,500 shares—equivalent to 0.09% of the shares outstanding at the mandate date—leaving authority for up to 102.47 million additional repurchases. In line with Hong Kong Stock Exchange rules, Kindstar is subject to a moratorium on issuing new shares or disposing of treasury shares until 20 August 2026.